Rice web server helps identify COVID-19 drug candidates

Rice University researchers have introduced an online portal to help researchers screen COVID-19 drug candidates that might attack specific proteins of the SARS-CoV-2 virus.

Lydia Kavraki, a computer scientist at the George R. Brown School of Engineering, and her colleagues at the University of Houston, the University of Edinburgh, Scotland, and the Federal University of Ceará, Brazil, have posted a "user-friendly" web server offering scientists the chance to screen their drug candidates virtually in relation to known protein binding pockets on the SARS-CoV-2 virus.

Better yet, the program incorporates what they say is an often-overlooked factor in computational models of these pockets: their flexibility.

The project, detailed in an open-access paper in Computers in Biology and Medicine, incorporates models of three drug targets - main protease (Mpro), RNA-dependent RNA polymerase (RdRp) and Papain-like protease (PLpro) - for ensemble docking through DINC-COVID.

The ensemble docking approach allows researchers to screen candidate ligands (reactive molecules) against different conformations of SARS-CoV-2 proteins and their binding pockets. DINC-COVID then scores the ligands' success at binding.

DINC stands for "Docking INCrementally," a protocol developed by Kavraki’s lab in 2013 to speed protein-peptide docking simulations that help researchers design drugs, vaccines and other processes involving large ligands. An upgraded version led by Kavraki and Dinler Antunes, then a postdoctoral researcher in her lab and now an assistant professor at the University of Houston, appeared in 2017.

The new iteration relies on the “impressive number” of SARS-CoV-2 protein structures that have been resolved so far. Understanding these structures allows researchers to find binding partners that could, ideally, deactivate the virus.

The study also offers a literal twist, best represented by the main protease, a docking site on the virus that has been the focus of much attention over the past 18 months. Researchers have found the Mpro site can substantially distort its shape in response to binding, allowing it to accommodate a diverse set of potential ligands.

That malleability makes Mpro and other sites hard to simulate, with a much higher computational cost, said Rice postdoctoral researcher and co-author Mauricio Rigo. "Unlike other servers, the proteins we are making available aren’t static; they’re not a single conformation,” he said. “We use states to reflect the dynamics of this protein in a physiological environment."

The team used several programs to narrow the ensembles from the 100,000 possible conformations generated by a molecular dynamics simulation, for instance, to a set of representative conformations. That lets the researchers decouple ensemble generation from docking within DINC-COVID, saving hours or days on complicated calculations.

"We believe this was the right way to go," Rigo said. "Our tests of the algorithm gave us a good match with experimental results."

Along with Mpro, the team modeled ensembles of catalytic binding sites on PLpro and RdRp. For Mpro, they modeled its catalytic and allosteric binding sites, for a total of 12 ensembles.

"We chose them because these can be targeted by different drugs," said Sarah Hall-Swan, a Rice graduate student and co-lead author of the paper. "When you're trying to find a drug to inhibit a virus, you're going to look for the protein parts that are important for that virus to function and try to inhibit them."

The lab is working to expand the number of ensembles available in DINC-COVID.

"We are very pleased with the response of the community to our work," Kavraki said. "DINC-COVID has already been used by about 500 researchers in 16 different countries, while our earlier web server DINC has been accessed by 11,000 users. We hope DINC-COVID will help shed light on the complex mechanisms of infection by SARS-CoV-2."

Didier Devaurs, a former Rice postdoctoral researcher and now a research fellow at the University of Edinburgh, is co-lead author of the paper. Geancarlo Zanatta, an associate professor of physics at the Federal University of Ceará, is a corresponding author. Kavraki is the Noah Harding Professor of Computer Science, a professor of bioengineering, mechanical engineering and electrical and computer engineering and director of the Ken Kennedy Institute.

Sarah Hall-Swan, Didier Devaurs, Mauricio M Rigo, Dinler A Antunes, Lydia E Kavraki, Geancarlo Zanatta.
DINC-COVID: A webserver for ensemble docking with flexible SARS-CoV-2 proteins.
Computers in Biology and Medicine, 2021. doi: 10.1016/j.compbiomed.2021.104943

Most Popular Now

Findings open way for personalised MS treatment

Currently available therapies to treat multiple sclerosis (MS) lack precision and can lead to serious side effects. Researchers at Karolinska Institutet in Sweden have no...

Pfizer shares top-line results from Phase 2/3 EPIC…

Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating...

Pfizer and Biohaven's VYDURA® (rimegepant) granted…

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorizatio...

A smarter way to develop new drugs

Pharmaceutical companies are using artificial intelligence to streamline the process of discovering new medicines. Machine-learning models can propose new molecules that ...

Foundation S: Sanofi's new philanthropic spearhead

Sanofi today launches Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partners...

Cognitive impairment from severe COVID-19 equivale…

Cognitive impairment as a result of severe COVID-19 is similar to that sustained between 50 and 70 years of age and is the equivalent to losing 10 IQ points, say a team o...

SK bioscience and GSK's adjuvanted COVID-19 vaccin…

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s...

Investigational COVID mucosal vaccine protects aga…

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spr...

Using AI to analyze large amounts of biological da…

Researchers at the University of Missouri are applying a form of artificial intelligence (AI) - previously used to analyze how National Basketball Association (NBA) playe...

Asthma drug can block crucial SARS-CoV-2 protein

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, ac...

Recurring brain tumor growth is halted with new dr…

When a non-metastatic brain tumor - a meningioma - recurs after surgery and radiation treatment, a patient is out of options. No drugs are approved for these aggressive t...

Pfizer to acquire Biohaven Pharmaceuticals

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) have entered into a definitive agreement under which Pfizer will acquire Biohaven, t...